All News
ACR Clinical Guidelines Flawed by Low Evidence
JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations.
Read ArticleNew EULAR/ACR Classification Criteria for Adult and Juvenile Myositis
The European League Against Rheumatism and the American College of Rheumatology (EULAR/ACR) have developed classification criteria for idiopathic inflammatory myopathies (IIM) based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% ad
Read ArticleStelara FDA Approved for Use in Adolescent Psoriasis
Johnson & Johnson has announced that they have received an expanded FDA approval for the use of ustekinumab (Stelara) in treating adolescent patients, aged 12 and over, with moderate to severe plaque psoriais.
Read ArticleBiologic Use in Adult-Onset Still's Disease
Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.
Read ArticleKids with Crohn's have Profound MSK Deficits - but No Increase in Fractures
Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract, is also known for its propensity to affect the musculoskeletal system.
Read ArticleJIA Worsens Quality of Life Long into Adulthood
Adult patients with a history of juvenile idiopathic arthritis (JIA) showed poorer health-related quality of life decades later, compared with individuals who were healthy as children -- even if they were in clinical remission, reported researchers in Norway.
Read ArticlePediatric Consensus on Comorbidity Assessments
Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.
Read ArticleFDA Approves Abatacept for Pediatric Use
Subcutaneous (SC) abatacept (Orencia) is now available for use in patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic (JIA) according to Bristol-Myers Squibb.
Read ArticleThe RheumNow Week in Review – 2 June 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com.
Read ArticleBoth Undertreatment and Overtreatment Common in JIA
Kimme L. Hyrich, MD, PhD, of the University of Manchester in the United Kingdom, and colleagues point out that because of the lack of consensus in diagnostic criteria, "the same child could be classified as 'in clinically inactive disease' or having active disease at the same time point between clinicians or hospitals."
Read ArticleGolimumab Fails in Polyarticular Juvenile Arthritis
Treatment options for children with active polyarticular juvenile idiopathic arthritis (polyJIA) have lagged behind that seen with adult rheumatoid arthritis.
Read ArticleThe RheumNow Week in Review - 26 May 2017
Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:
Read ArticleNon-Prescribed Opioid Abuse by Young Adults
Journal of Addiction Medicine reported that young adults often are "self-medicated" to manage pain.
Read ArticleAdalimumab Effective in Pediatric Plaque Psoriasis
Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis. The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.
Read ArticleThe RheumNow Week in Review – 5 May 2017
Dr Jack Cush reviews highlights from the news last week on RheumNow.com:
Read ArticleEnthesitis-Related Arthritis in Children
Enthesitis-related arthritis (ERA) is an emerging subset of juvenile idiopathic arthritis (JIA) recognized for its distinctive clinical characteristics.
Read ArticleNEJM: Adalimumab and MTX Effective in JIA Uveitis
The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab and methotrexate is effective in reducing ocular flares in juvenile idiopathic arthritis with uveitis.
Read ArticleFDA Approves Renflexis as Second Infliximab Biosimilar
On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD. In early developmental trials this agent was also called SB2.
Read ArticleHealthy Bones Formed During Adolescence
An article in the Journal of Bone and Mineral Research reports that physical activity during adolescence is an important determinant in bone strength. (Citation source http://buff.ly/2oph6vO)
Read ArticleThe RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Read Article